Matinas BioPharma Holdings, Inc.
MTNB
$2.13
$0.3922.41%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.29% | 71.57% | -58.69% | 29.40% | 5.63% |
| Total Depreciation and Amortization | -49.38% | -46.67% | 2.92% | 2.52% | 2.99% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | 59.09% |
| Total Other Non-Cash Items | 268.62% | -97.89% | 255.81% | -20.20% | -24.12% |
| Change in Net Operating Assets | -133.92% | 58.26% | 110.82% | -336.22% | -40.82% |
| Cash from Operations | 34.93% | 65.21% | 23.35% | 20.80% | -41.63% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -83.11% | 776.91% | -145.91% |
| Cash from Investing | -- | -- | -83.11% | 789.85% | -147.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | -100.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -82.35% | 3,007.55% | 0.00% | -6,600.00% | 919,000.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.69% | 90.31% | -85.86% | 282.22% | -21.45% |